Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.84 percent decrease over losses of $(0.51) per share from the same period last year.
MediPharm Touts Strong Q3 Revenue Growth, Continues To Expand Internationally
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced on Monday its financial results for the three months ended Sept. 30, 2022.
